DUBLIN – On the basis that 11 percent of something is better than 100 percent of nothing, Vital Therapies Inc., is throwing in its lot with privately held German drug development firm Immunic AG in a reverse merger that is being encouraged with an additional investment of €26 million (US$29.7 million) from Immunic's shareholders. The deal will transform Planegg-Martinsried-based Immunic into a Nasdaq-listed company, and it is embracing its new identity by moving its headquarters from the Munich region to Boston.